Show news: from last 30 days (default), 60 days, 90 days, last visit or all

Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023.

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

Guidance and information on prescribing and supply of cannabis-based products for medicinal use

6th November 2018

Guidance is now available to help health professionals with the prescribing and supply of cannabis-based products for medicinal use, which were rescheduled in England, Wales and Scotland on the 1 November 2018 from Schedule 1 to Schedule 2 (see our previous news item).

Cannabis-based products for medicinal use: Guidance to clinicians (NHS England)

Guidance on the supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in ‘specials’ (MHRA)

Interim clinical guidelines have also been produced by the Royal College of Physicians (RCP) and the British Paediatric neurology Association (BPNA), to support prescribing decisions.

RCP interim guidance

BPNA interim guidance

Finally, information for patients and the public is available on the NHS website.

Editor’s notes

Also see the recently updated PCF Cannabinoids, which reflects and was used to help inform the RCP guidance for use in palliative care.

The legislative changes do not apply to;